Clinical trial
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00002985 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00002985 |
|---|---|
| Title | Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma |
| Official title | Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | daunorubicin hydrochloride, pegylated liposomal doxorubicin hydrochloride |
| Start date | Nov 1, 1996 |
| Primary completion | Jan 1, 2007 |
| First posted | May 19, 2004 |
| Last update posted | Feb 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: